{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T08:47:29Z","timestamp":1783241249985,"version":"3.54.6"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["RO1 NS33202"],"award-info":[{"award-number":["RO1 NS33202"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"crossref","award":["1P20GM103642"],"award-info":[{"award-number":["1P20GM103642"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.expneurol.2014.10.008","type":"journal-article","created":{"date-parts":[[2014,10,23]],"date-time":"2014-10-23T01:30:56Z","timestamp":1414027856000},"page":"88-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome"],"prefix":"10.1016","volume":"270","author":[{"given":"Haipeng","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary E.","family":"Grajales-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivianette","family":"Alicea-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose G.","family":"Grajales-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KaReisha","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pytel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"B\u00e1ez-Pag\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Lasalde-Dominicci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2014.10.008_bb0110","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1176\/ajp.154.7.963","article-title":"Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study","volume":"154","author":"Amsterdam","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.expneurol.2014.10.008_bb0060","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s00415-011-6204-9","article-title":"A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome","volume":"259","author":"Chaouch","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0065","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.nmd.2006.02.009","article-title":"Long-term improvement of slow-channel congenital myasthenic syndrome with fluoxetine","volume":"16","author":"Colomer","year":"2006","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0005","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ana.410110603","article-title":"A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel","volume":"11","author":"Engel","year":"1982","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0070","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/mus.23534","article-title":"Slow channel congenital myasthenic syndrome responsive to a combination of fluoxetine and salbutamol","volume":"47","author":"Finlayson","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.expneurol.2014.10.008_bb0050","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1749-6632.1998.tb10928.x","article-title":"AChR channel blockade by quinidine sulfate reduces channel open duration in the slow-channel congenital myasthenic syndrome","volume":"841","author":"Fukudome","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0010","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/ana.410390607","article-title":"A beta-subunit mutation in the acetylcholine receptor channel gate causes severe slow-channel syndrome","volume":"39","author":"Gomez","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0075","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1523\/JNEUROSCI.17-11-04170.1997","article-title":"Slow-channel transgenic mice: a model of postsynaptic organellar degeneration at the neuromuscular junction","volume":"17","author":"Gomez","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0080","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1749-6632.1998.tb10923.x","article-title":"Genetic manipulation of AChR responses suggests multiple causes of weakness in slow-channel syndrome","volume":"841","author":"Gomez","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0015","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1523\/JNEUROSCI.22-15-06447.2002","article-title":"Active calcium accumulation underlies severe weakness in a panel of mice with slow-channel syndrome","volume":"22","author":"Gomez","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ana.10077","article-title":"Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms","volume":"51","author":"Gomez","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0115","first-page":"503","article-title":"Pharmacokinetics of second generation antidepressants: fluoxetine","volume":"27","author":"Goodnick","year":"1991","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0120","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/tpj.2012.21","article-title":"Transgenic mouse model reveals an unsuspected role of the acetylcholine receptor in statin-induced neuromuscular adverse drug reactions","volume":"13","author":"Grajales-Reyes","year":"2013","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0035","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1172\/JCI30383","article-title":"Calpain activation impairs neuromuscular transmission in a mouse model of the slow-channel myasthenic syndrome","volume":"117","author":"Groshong","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0055","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1212\/01.WNL.0000061483.11417.1B","article-title":"Treatment of slow-channel congenital myasthenic syndrome with fluoxetine","volume":"60","author":"Harper","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2014.10.008_bb0095","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/10520296409063307","article-title":"The glyoxal bis(2-hydroxyanil) method modified for localizing insoluble calcium salts","volume":"39","author":"Kashiwa","year":"1964","journal-title":"Stain. Technol."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0125","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/00005072-198205000-00005","article-title":"Neostigmine myopathy is a calcium ion-mediated myopathy initially affecting the motor end-plate","volume":"41","author":"Kawabuchi","year":"1982","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0100","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3181\/00379727-70-17013","article-title":"A histochemical method for localizing cholinesterase activity","volume":"70","author":"Koelle","year":"1949","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0105","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/sj.onc.1210713","article-title":"Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling","volume":"27","author":"Lee","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.expneurol.2014.10.008_bb0130","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1083\/jcb.82.3.811","article-title":"Agonist-induced myopathy at the neuromuscular junction is mediated by calcium","volume":"82","author":"Leonard","year":"1979","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0090","first-page":"569","article-title":"Ketamine and xylazine anesthesia in the mouse","volume":"74","author":"Mulder","year":"1979","journal-title":"Vet. Med. Small Anim. Clin."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0135","doi-asserted-by":"crossref","first-page":"9390","DOI":"10.1074\/jbc.275.13.9390","article-title":"Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139","volume":"275","author":"Rogakou","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0140","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ana.10823","article-title":"Focal caspase activation underlies the endplate myopathy in slow-channel syndrome","volume":"55","author":"Vohra","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0085","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.nbd.2006.04.018","article-title":"Activation of apoptotic pathways at muscle fiber synapses is circumscribed and reversible in a slow-channel syndrome model","volume":"23","author":"Vohra","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0025","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ceca.2006.07.007","article-title":"Inositol-1,4,5-triphosphate receptors mediate activity-induced synaptic Ca2+ signals in muscle fibers and Ca2+ overload in slow-channel syndrome","volume":"41","author":"Zayas","year":"2007","journal-title":"Cell Calcium"},{"key":"10.1016\/j.expneurol.2014.10.008_bb0030","doi-asserted-by":"crossref","first-page":"15269","DOI":"10.1523\/JNEUROSCI.3766-11.2011","article-title":"Skeletal muscle IP3R1 receptors amplify physiological and pathological synaptic calcium signals","volume":"31","author":"Zhu","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0040","doi-asserted-by":"crossref","first-page":"7308","DOI":"10.1523\/JNEUROSCI.0224-13.2013","article-title":"Skeletal muscle calpain acts through nitric oxide and neural miRNAs to regulate acetylcholine release in motor nerve terminals","volume":"33","author":"Zhu","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2014.10.008_bb0045","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/hmg\/ddt397","article-title":"Selective inhibition of caspases in skeletal muscle reverses the apoptotic synaptic degeneration in slow-channel myasthenic syndrome","volume":"23","author":"Zhu","year":"2014","journal-title":"Hum. Mol. Genet."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488614003446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488614003446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T10:45:22Z","timestamp":1565952322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488614003446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":28,"alternative-id":["S0014488614003446"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2014.10.008","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2014.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}